ANTI-CADM1 ANTIBODY

WIPO Patent Application WO/2022/239766

A1

The purpose of the present invention is to provide an antibody that binds to CADM1 expressed on a cell and that can singly induce intracellular internalization thereof. Specifically, the present invention pertains to an antibody or an antigen-binding fragment thereof that binds to Cell adhesion molecule 1 (CADM1) and that induces, by binding to CADM1 on a cell surface, intracellular internalization thereof. Representative examples of the antibody include an antibody having a heavy chain CDR1 including an amino acid sequence represented by SEQ ID NO: 1, a heavy chain CDR2 including an amino acid sequence represented by SEQ ID NO: 2, a heavy chain CDR3 including an amino acid sequence represented by SEQ ID NO: 3, a light chain CDR1 including an amino acid sequence represented by SEQ ID NO: 4, a light chain CDR2 including an amino acid sequence represented by SEQ ID NO: 5, and a light chain CDR3 including an amino acid sequence represented by SEQ ID NO: 6.

NAKANO KAZUMI (JP)
WATANABE TOSHIKI (JP)
TSUMOTO KOUHEI (JP)
TANABE AKI (JP)
TAKAHASHI YOSHIAKI (JP)

PCT/JP2022/019787

November 17, 2022

May 10, 2022

Click for automatic bibliography generation  

UNIV TOKYO (JP)
UNIV OF THE RYUKYUS (JP)

A61K39/395; A61K45/00; A61K47/68; A61P35/02; C07K16/18; C07K16/28; C07K16/46

JP2012519492A

2012-08-30

CHILMI SYAHRUL; NAKAHATA SHINGO; FAUZI YANUAR RAHMAT; ICHIKAWA TOMONAGA; TANI CHIKAKO; SUWANRUENGSRI MATHUROT; YAMAGUCHI RYOJI; MA: "Development of anti-human CADM1 monoclonal antibodies as a potential therapy for adult T-cell leukemia/lymphoma", INTERNATIONAL JOURNAL OF HEMATOLOGY., ELSEVIER SCIENCE PUBLISHERS., NL, vol. 112, no. 4, 12 July 2020 (2020-07-12), NL , pages 496 - 503, XP037256734, ISSN: 0925-5710, DOI: 10.1007/s12185-020-02939-1

OKUHARA Koji (JP)

View/Download PDF      PDF Help

Previous Patent: AMYLOID-β AGGREGATION INHIBITOR, PHARMACEUTICAL COMPOSITION FOR AMYLOID-β AGGREGATION DISEASES, AN...

Next Patent: LAMINATE AND DISPLAY DEVICE